A robust culture system to generate neural progenitors with gliogenic competence from clinically relevant induced pluripotent stem cells for treatment of spinal cord injury

Yasuhiro Kamata1,2 | Miho Isoda1,3 | Tsukasa Sanosaka1 | Reo Shibata2 | Shuhei Ito2 | Toshiki Okubo2 | Munehisa Shinozaki1 | Mitsuhiro Inoue1,3 | Ikuko Koya1 | Shinsuke Shibata1 | Tomoko Shindo1 | Morio Matsumoto2 | Masaya Nakamura2 | Hideyuki Okano1,© | Narihito Nagoshi2 | Jun Kohyama1

1Department of Physiology, Keio University School of Medicine, Tokyo, Japan
2Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan
3Regenerative & Cellular Medicine Kobe Center, Sumitomo Dainippon Pharma Co., Ltd, Kobe, Japan

Correspondence
Jun Kohyama, MD, PhD, Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan.
Email: jkohyama@a7.keio.jp

Funding information
General Insurance Association of Japan; Japan Agency for Medical Research and Development (AMED), Grant/Award Numbers: 18m040422h0001, 18bm0204001h003, 18bm040422h0201; Research Center Network for Realization of Regenerative Medicine of the Japan Science and Technology Agency (JST)

Abstract
Cell-based therapy targeting spinal cord injury (SCI) is an attractive approach to promote functional recovery by replacing damaged tissue. We and other groups have reported the effectiveness of transplanting neural stem/progenitor cells (NS/PCs) derived from human induced pluripotent stem cells (hiPSCs) in SCI animal models for neuronal replacement. Glial replacement is an additional approach for tissue repair; however, the lack of robust procedures to drive iPSCs into NS/PCs which can produce glial cells has hindered the development of glial cell transplantation for the restoration of neuronal functions after SCI. Here, we established a method to generate NS/PCs with gliogenic competence (gNS/PCs) optimized for clinical relevance and utilized them as a source of therapeutic NS/PCs for SCI. We could successfully generate gNS/PCs from clinically relevant hiPSCs, which efficiently produced astrocytes and oligodendrocytes in vitro. We also performed comparison between gNS/PCs and neurogenic NS/PCs based on single cell RNA-seq analysis and found that gNS/PCs were distinguished by expression of several transcription factors including HEY2 and NFIB. After gNS/PC transplantation, the graft did not exhibit tumor-like tissue formation, indicating the safety of them as a source of cell therapy. Importantly, the gNS/PCs triggered functional recovery in an SCI animal model, with remyelination of demyelinated axons and improved motor function. Given the inherent safety of gNS/PCs and favorable outcomes observed after their transplantation, cell-based medicine using the gNS/PCs-induction procedure described here together with clinically relevant iPSCs is realistic and would be beneficial for SCI patients.

KEYWORDS
HLA-homo, induced pluripotent stem cells, neural stem progenitor cells, oligodendrocyte, remyelination, spinal cord injury

Yasuhiro Kamata and Miho Isoda are co-first authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.
**1 | INTRODUCTION**

The central nervous system (CNS) has a limited capacity to regenerate; therefore, any loss of function by traumatic injury is mostly irreversible. Spinal cord injury (SCI) is a traumatic injury to the CNS that results in severe physical impairments, including permanent paralysis, sensory disturbance, and bladder dysfunction. The number of new cases annually is approximately 120,000 in the United States and 5000 in Japan. However, approaches to treat SCI patients are currently limited.

In recent years, cell transplantation therapies are considered to be effective in SCI animal models, and preclinical evaluations have been initiated. As a cell source for the therapies, human induced pluripotent stem cells (hiPSCs) have attracted particular interest due to a limited number of ethical concerns, as they are directly generated from somatic cells. We have reported the efficacy of cell transplantation in SCI animal models using neural stem/progenitor cells (NS/PCs) derived from hiPSCs and the integration of hiPSC-derived neurons into the host neuronal networks. However, mouse gliogenic NS/PCs were reported to produce more favorable outcomes than neurogenic NS/PCs after transplantation into a SCI animal model, indicating additional processes mediated by gliogenic NS/PCs can be therapeutic in addition to neuronal replacement by grafted NS/PCs. Moreover, transplantation of NS/PCs derived from myelin-deficient shiverer mice, produced less functional recovery after transplantation into injured spinal cord, indicating the importance of remyelination in the repair process by grafted NS/PCs. These results indicate the importance of glial cells including oligodendrocytes for treatment of SCI. Since hiPSCs can serve as an unlimited and scalable source of somatic cells, successful derivation of glial cells would benefit a broad range of neurological disorders including SCI. However, it is noteworthy that hiPSC-NS/PCs predominantly differentiate into neurons both in vitro and in vivo. Accordingly, numerous attempts have been made to improve the generation of glial cells including oligodendrocytes from hiPSCs. However, these procedures often required long duration to generate glial cells and/or complicated techniques. Moreover, most procedures are optimized for iPSCs generated in individual laboratories. There is limited information for reproducibility of differentiation over multiple iPSCs. Therefore, a standardized protocol to generate glial cells from iPSCs has not been developed.

In addition, there is another issue to be in account. Numerous studies have demonstrated the potency of iPSCs in regenerative medicine; however, most of these studies used iPSCs that were not generated for clinical use. Generation and validation of clinically relevant iPSCs is costly and time-consuming, which hinders the preclinical evaluation of iPSCs. Thus, there is a need to develop a cell bank of iPSCs, which provides qualified iPSCs to researchers. Then, each researcher would conduct preclinical evaluation of iPSC-derivatives without generating and validating iPSCs by himself. The Center for iPSC Cell Research and Application (CiRA) at Kyoto University, a core center for iPSC research in Japan, was funded by the Japanese government to prepare clinical grade iPSCs from donors who were homozygous for the three major human leucocyte antigen (HLA) loci haplotypes (HLA-A, HLA-B, and HLA-DR) (HLA-homozygous), which would reduce immune rejection after allogenic transplantation. However, there is no established protocols to generate NS/PCs optimized for therapeutic intervention, and, most importantly, their safety and therapeutic efficacy after transplantation remain unknown.

Here, we aimed to establish and optimize a robust protocol to produce NS/PCs with gliogenic competence (gNS/PCs) from clinically relevant iPSCs, from which oligodendrocytes can be generated. We also assessed the efficacy and safety of the NS/PCs in a rodent model of SCI (Figure 1A). This study is the first evaluation of clinically relevant HLA-homozygous iPSCs in an SCI model.

**2 | MATERIALS AND METHODS**

See further details in the Supporting Information Materials and Methods.

### 2.1 | Cell culture and neural induction

The hiPSC lines (WJ14s01, WJ14s02, WJ23s01, and WJ23s02) were established at CiRA from umbilical cord blood cells obtained from HLA-homozygous healthy donors (homozygous for HLA-A*24:02; HLA-B*52:01; HLA-DRB1*15:02 haplotypes) under xeno-free and feeder-free conditions via the transduction of reprogramming factors (OCT3/4, SOX2, KLF4, L-MYC, dominant-negative p53, and EBNA1) using episomal vectors. Most experiments were performed using WJ14s01. Other lines were used for validation of the protocol to generate gNS/PCs as indicated in the manuscript. hiPSCs were maintained by the feeder-free iPSC culture method. For gNS/PCs induction, hiPSCs were dissociated into single cells using TrypLE Select (Thermo Fisher Scientific) and reaggregated to form embryoid bodies (EBs) using 96-well low cell-adhesion plates (Sumitomo Bake-lite) at a density of 9000 cells/well in StemFit AK03N (Ajinomoto) without fibroblast growth factor 2 (FGF2) supplemented with 100 nM LDN193189, 3 μM SB431542, and 3 μM CHIR99021 (all from...
Stemgent) at 37°C and 5% CO₂/5% O₂ for 7 days. On day 7, the medium was switched to StemFit AK03N without FGF2 supplemented with 1 μM retinoic acid (RA, Sigma). The medium was changed every day. On day 14, EBs were transferred into ultralow attachment culture flasks (Coming) and cultured in proliferation medium supplemented with 1 μM RA and 1 μM purmorphamine (PM, Merck Millipore) at 37°C and 5% CO₂/20% O₂. Proliferation medium is a mixture of DMEM/F12 (Wako) containing 1% N2 (Thermo Fisher Scientific), 2% B-27 without Vitamin A (Thermo Fisher Scientific), 60 ng/mL triiodo-L-thyronine (T3, Sigma), 10 ng/mL Platelet-derived growth factor (PDGF)-AA (PeproTech), 20 ng/mL FGF2 (PeproTech), 10 ng/mL epidermal growth factor (EGF, PeproTech), 10 ng/mL insulin growth factor 1 (IGF-1, R&D systems), and 10 ng/mL neurotrophin 3 (NT-3, R&D Systems). On day 21, EBs were enzymatically dissociated into single cells using TrypLE Select, and the dissociated cells were cultured in suspension at a density of 1.0 x 10⁵ cells/mL in proliferation medium.
proliferation medium supplemented with 1 μM PM to generate the first neurospheres. The medium was changed every 7 days. After 14 days, the first neurospheres were dissociated in the same manner as described above and cultured in proliferation medium without PM. Passaging was carried out once every 14 to 28 days thereafter. The third passage neurospheres were used for transplantation. Neuronal and glial differentiation was performed as previously described.

Undissociated 15 to 20 neurospheres were plated on 8-well chamber glass slides coated with 1% growth factor reduced Matrigel (Corning), and cultured in differentiation medium that consisted of KBM Neural Stem Cell (KOHJIN BIO) supplemented with 2% B27, 1% nonessential amino acids (Thermo Fisher Scientific), 60 ng/mL T3, 10 ng/mL NT-3, 10 ng/mL Leukemia Inhibitory Factor (Millipore), and 25 ng/mL Ciliary Neurotrophic Factor (Peprotech) for 4 weeks in a humidified atmosphere of 5% CO2. Half of the medium was changed every 2 or 3 days. The neurogenic NS/PCs were kindly provided by Dr Yonehiro Kanemura and cultured as previously described.

2.2 SCI animal model and feeder-free hiPSCs (ffiPSC)-gNS/PCs transplantation

Eight-week-old female nonobese diabetic-severe combined immunodeficiency mice (Charles River Laboratories) were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Contusive SCI was induced at the level of the tenth thoracic spinal vertebra using an Infinite Horizon impactor (60-70 kdyn; Precision Systems and Instrumentation), as described previously. After SCI, 12.5 mg/kg ampicillin was administered intramuscularly. Seven days after injury, all the mice were evaluated for motor function, and mice with a Basso Mouse Scale (BMS) score of 2.5 or higher were included in the study. The SCI mice were randomly assigned to each group (15 mice per group). For gNS/PCs group mice, 9 days after injury, ffiPSC-gNS/PCs (5 × 105 cells in 2 μL of phosphate-buffered saline [PBS]) were transplanted into the lesion epicenter of each mouse with a Hamilton syringe with a 28 G metal needle using a microstereotaxic injection system (KDS310; Muromachi-Kikai Co., Ltd.). An equal volume of PBS was similarly injected into PBS group mice in place of the ffiPSC-gNS/PCs. The injected depth was 0.3 to 0.8 mm and injection speed was 1 μL/min. A mouse of gNS/PCs group and three mice of PBS group died during the observation period and were excluded from the study. For evaluation of tumorigenicity of ffiPSC-gNS/PCs, intracerebral ffiPSC-gNS/PCs transplantation was performed with stereotactic injection of 1.0 × 106 cells in 4 μL of PBS through a 22 G needle into the striatum of 22-week-old female F344/NJcl-rnu/rnu rats (Clea Japan) (1 mm anterior and 3 mm lateral from bregma and 5.5 mm below the brain surface) and injection speed was 6 μL/min.

2.3 Motor function analyses

Hind limb locomotor function was evaluated for 12 weeks after transplantation using the BMS. At 12 weeks after transplantation, a rotating rod apparatus, a treadmill gait analysis, and a kinematics were performed. Detailed methods are described in the Supporting Information.

2.4 Quantification and statistical analyses

Statistical analyses were performed using SPSS version 25 (Japan IBM). All data are reported as the mean ± SEM. The normality of the distribution of data points was verified using Shapiro-Wilk test. The Mann-Whitney U test was used for H&E staining (control group, n = 6; ffiPSC-gNS/PCs group, n = 6), Luxol fast blue (LFB) staining (control group, n = 6; ffiPSC-gNS/PCs group, n = 6), myelin basic
protein (MBP) area (control group, n = 6; ffiPSC-gNS/PCS group, n = 6), biotin dextran amine (BDA)-labeled RtST (control group, n = 6; ffiPSC-gNS/PCS group, n = 6), body weight gain and loss (control group, n = 12; ffiPSC-gNS/PCS group, n = 14), kinematic analyses (control group, n = 5; ffiPSC-gNS/PCS group, n = 8), Treadmill gait analysis (control group, n = 12; ffiPSC-gNS/PCS group, n = 14), rotarod test (control group, n = 12; ffiPSC-gNS/PCS group, n = 14), and H-reflex (control group, n = 9; ffiPSC-gNS/PCS group, n = 7). Repeated-measures two-way analysis of variance (ANOVA), followed by the Turkey-Kramer test, was used for the BMS analysis (control group, n = 12; ffiPSC-gNS/PCS group, n = 14). In each case, *P < .05 and **P < .01 were statistically significant.

3 | RESULTS

3.1 | Generation of glial progenitor-enriched NS/PCS from feeder-free HLA-homozygous hiPSCs

To realize clinical application of NS/PCSs derived from iPSCs, we focused on clinically relevant feeder-free hiPSCs (ffiPSCs) provided by iPSC bank in Cira. These iPSCs had been established from HLA-homozygous donors to lower the immunogenicity of iPSC-derivatives (Figure 1A). Since neural differentiation protocols usually depend on the innate differentiation capacity of the individual iPSC clones and are successful for a limited number of iPSC clones,33 we were motivated to modify previously reported neural induction procedures for NS/PCSs, which had been examined over multiple iPSC clones established from different somatic tissue origins.29,34 Given that the NS/PCSs generated from this procedure were less gliogenic,29 we attempted to determine experimental conditions to generate NS/PCS containing glial progenitors using the ffiPSCs. Initially, we applied this protocol on the ffiPSCs derived from umbilical cord blood cells (WJ14s01) and examined differentiation capacity of NS/PCSs. As shown in Figure 1B, we successfully differentiated ffiPSCs into NS/PCSs which mainly produced neurons and, as expected, glial differentiation capacity was limited: any oligodendrocytes judged by the expression of oligodendrocyte marker O4 was not detected. Then, we modified this protocol to the trigger precocious glial differentiation from NS/PCSs and determined the protocols as follows. Among various cytokines and/or chemical compounds, we chose CHIR99021 (CHIR), a GSK-3β inhibitor,35 and RA for astrocyte-generation to accelerate differentiation of NS/PCSs, as previously reported.36-39 As shown in Figure 1B, we exposed ffiPSCs to CHIR and dual Smad inhibitors for 7 days, followed by treatment with RA for 14 days. To enhance oligodendrocyte differentiation, we chose purmorphamine (PM), a sonic hedgehog agonist that ventralizes neural tissues, to provide a permissive environment for oligodendrocytes and astrocytes and oligodendrocyte-committed markers, including OLIG2 and platelet-derived growth factor receptor α (PDGFRα). Among them, NFIA and OLIG2 were of interests given their essential role for generation of astrocytes and oligodendrocyte, respectively.40,43-45 OLIG2 and NFIA were highly expressed in the neurons (19.67% ± 6.32% and 81.26% ± 3.36%, respectively), indicating that the current procedures enabled to convert iPSCs to NS/PCSs with gliogenic capacity. In contrast, consistent with the neuron-biased differentiation capacity of the iPSC-derived NS/PCSs,29 these neurogenic NS/PCSs exhibited expression of REST in the neurons and NFIA in the NS/PCSs were almost negligible (0.54% ± 0.23% and 0%, respectively) (Figure 1E). Taken together, these observations indicated that the NS/PCSs prepared using the current protocol contained high numbers of NS/PCSs which could produce glial cells; thus, we designated the NS/PCSs derived from ffiPSCs as NS/PCSs with gliogenic competence (ffiPSC-gNS/PCSs).

We further applied the protocol to three additional clones of ffiPSCs (WJ14s02, WJ23s01, and WJ23s02) and consistently obtained NS/PCSs that produced astrocytes and oligodendrocytes, indicating that the procedure was robust enough to generate NS/PCSs from the ffiPSCs (data not shown).

Tumorigenicity is one of potential barriers to put iPS-derived cells into clinical setting.66 Accordingly, we examined the safety of ffiPSC-gNS/PCSs by transplanting them into the striatum of immunodeficient rats as previously described (Figure 1F). We analyzed the graft about 6 months after the transplantation and detected no visible tumorigenic mass in the transplanted immunodeficient animals (data not shown). Since some iPSC-NS/PCSs have been reported to exhibit tumorigenicity with the expression of OCT3/4 (a marker for pluripotent stem cells),68 we further evaluated the histological features of the grafts by immunostaining with antibodies against OCT3/4 and Ki67 (a marker for proliferative cells). Although some cells were still positive for Ki67, we detected no OCT3/4-expressing cells in the graft (Figure 1F). Therefore, we found that ffiPSC-gNS/PCSs were less tumorigenic.

3.2 | Transcriptome signature of ffiPSC-gNS/PCSs

To characterize the ffiPSC-gNS/PCSs, we performed RNA-seq analysis on ffiPSCs, ffiPSC-derived EBs, and ffiPSC-gNS/PCSs (P2 and P3).
Hierarchical clustering analysis of the transcriptional profiles of each sample exhibited clear separation between cell types (Figure 2B). To clarify the transcriptional difference, we examined the expression of cell type-specific marker genes for iPSCs (NANOG and OCT3/4), NS/PCs (SOX1 and SOX2), neurons (DCX and TUBB3), astrocytes (GFAP and AQP4) and oligodendrocytes (OLIG2 and NKX2.2) in the current samples. As shown in Figure 2C, iPSC markers were downregulated, while genes specific for NS/PCs and neurons were upregulated and maintained in EBs and fflipSC-gNS/PCs. In contrast, genes associated with astrocytes and oligodendrocytes were gradually upregulated in the gNS/PCs, indicating that fflipSC-gNS/PCs acquire the capacity to differentiate into glial cells during culture from EBs to gNS/PCs. Importantly, these genes were further upregulated from P2 to P3 fflipSC-gNS/PCs. We further cross-referenced our data set with the expression profiles of other types of neural progenitors, including neurogenic iPSC-NS/PCs12,13,18 and tripotent human fetal NS/PCs which produce astrocytes and oligodendrocytes in addition to neurons49 using Exatlas (https://lgsun.grc.nia.nih.gov/exatlas/). As expected, the gene expression profile of fflipSC-gNS/PCs was similar to that of human fetal NS/PCs while that of EBs was more similar to neurogenic iPSC-NS/PCs (Figure 2D). Notably, the trend of the gNS/PCs transcriptome becoming more similar to that of human fetal NS/PCs was apparent during cellular passage, revealing a transcriptional transition in fflipSC-gNS/PCs from P2 to P3. We selected differentially expressed genes between these cells (306 upregulated and 714 downregulated genes in P3 fflipSC-gNS/PCs) (Figure 2E) and performed Gene Ontology (GO) analysis to illuminate the biological functions (Figure 2F). While the GO term “cell adhesion” was identified in the downregulated gene set, GO terms obtained from upregulated genes included “nervous system development,” “neurotransmitter secretion,” “chemical synaptic transmission,” and “axon guidance,” indicating neuronal maturation during passaging.
In addition, “oligodendrocyte differentiation” was a notable term identified as it may explain the maturation of NS/PCs toward glial lineages.

To further characterize ffPSC-gNS/PCs, we performed single-cell RNA-seq (scRNA-seq) analysis of P3 ffPSC-gNS/PCs. As a reference, we used neurogenic iPSC-NS/PCs derived from the same
FIGURE 4  Differentiation potential of feeder-free hiPSCs (fiPSC)-gNS/PCs after transplantation. A, Representative H&E-stained images of sagittal sections of the spinal cord 12 weeks after transplantation. Positions of three axial section images in (C) are indicated with numbered lines. Scale bar = 200 μm. B, The distribution of transplanted cells was visualized by STEM121 immunoreactivity. The survival of transplanted cells at the lesion epicenter was confirmed. Scale bar = 200 μm. C, Human nuclear antigen (HNA) staining of axial sections at positions indicated in (A). The HNA+ grafted cells were integrated at the lesion epicenter (ii) and migrated rostrally (i) and caudally (iii). Scale bars = 200 μm. D, Characterization of the transplanted cells was determined using the cell type-specific markers indicated in the figure. Representative images of HNA+ grafted cells together with Ki67, OCT3/4, NESTIN, pan-ELAVL (Hu), GFAP, and adenomatous polyposis coli (APC) staining. Insets: Hoechst nuclear staining of each field. Scale bars = 20 μm. E, Quantification of the frequency of cell type-specific marker-positive cells among HNA+ transplanted cells 12 weeks after transplantation. GFAP, glial fibrillary acidic protein; gNS/PCs, neural stem/progenitor cells with gliogenic competence.
parental iPSCs (fiPSC-nNS/PCs)\textsuperscript{29} (Figures S1 and 3A). We sorted the NS/PCs into 96-well plates and processed them for scRNA-seq analysis.\textsuperscript{50} After quality control, 150 fiPSC-gNS/PCs and 91 fiPSC-nNS/PCs were further analyzed. Cell-clustering analysis by uniform manifold approximation and projection revealed clear separation of fiPSC-nNS/PCs and fiPSC-gNS/PCs (Figure 3B). The differential distribution of the clusters between these NS/PCs suggested that each group was substantially different at the transcriptome level (Figure 3B). For example, both NS/PCs shared similar SOX2 expression profiles; however, MKI67, a marker for proliferation, was mainly expressed in fiPSC-nNS/PCs, indicative of the progressive expandable capacity of neurogenic NS/PCs (Figure 3C). Since activation of Notch signaling is essential to acquire gliogenic potential of NS/PCs during mouse CNS development,\textsuperscript{51} we examined

---

**FIGURE 5** Legend on next page.
expression of HES5, a downstream effector of Notch signaling, and found that HES5 was mainly observed in the ffiPSC-gNS/PCs, suggesting gliogenic properties of ffiPSC-gNS/PCs (Figure 3C). Given that in our procedure to generate ffiPSC-gNS/PCs required RA, well-known for caudalizing activity on neural tissues during development, we examined difference in the regional identity. As shown in Figure S2, we examined expression of regional specific neural markers and observed ffiPSC-gNS/PCs held regional properties as caudalized neural tissues compared to ffiPSC-nNS/PCs, indicating regional identity in addition to differentiation capacity was altered. To characterize difference between these NS/PCs, we classified them based on transcriptome, and identified three clusters (C1-C3) (Figure 3D). Each cluster was characterized by marker genes that were visualized by the expression of selected cluster-defining gene sets (Figure 3E,F). Within the clusters, characteristic expression of neuronal genes, including ATCAY and ST18, was observed in cluster C3 (Figure 3E,F). Furthermore, Cluster C1 was characterized by expression of an early neuroectodermal marker, MMRN1. Frequency of cells harboring the features of Cluster C1 was high in ffiPSC-nNS/PCs, consistent with the high neurogenic capacity of ffiPSC-nNS/PCs (Figure 3G). In contrast, the expression of glial genes, including HEY2 and NFIB, was observed in Cluster C2 (Figure 3E,F). Interestingly, the Cluster C2 was highly enriched in ffiPSC-gNS/PCs, further supporting the glia-committed properties of ffiPSC-gNS/PCs compared with ffiPSC-nNS/PCs (Figure 3G).

3.3 | Transplanted ffiPSC-gNS/PCs survive, migrate, and differentiate into three neural lineages in vivo

We next examined whether the NS/PCs could promote functional recovery after CNS injury. We generated an SCI animal model by inducing contusive SCI with moderate severity at the 10th thoracic vertebrae level in adult female immunodeficient mice. Transplanted ffiPSC-gNS/PCs survive, and were widely spread throughout the injured spinal cord (Figure 4A,B). To examine the location of the graft-derived cells, we visualized the cells with HNA-specific antibodies and examined the distribution of the cells in axial sections of the spinal cord. We found HNA+ cells from the epicenter to +4 mm rostrocaudal in the ffiPSC-gNS/PCs group, indicating that the transplanted cells themselves migrated (Figure 4C). To further evaluate the capacity of differentiation of the NS/PCs, we examined the coexpression of HNA and cell type-specific markers at 12 weeks after transplantation, beginning with OCT3/4 and Ki67 for evaluation of tumorigenicity of the NS/PCs. Similar to the results observed in ffiPSC-gNS/PCs-transplanted striatum (Figure 1F), although 4.71% ± 0.20% of the HNA+ cells were positive for Ki67, there were no OCT3/4-expressing cells in the grafts (Figure 4D,E), indicating additional evidence of the safety of the ffiPSC-gNS/PCs. As predicted by the presence of Ki67+ proliferative cells, 17.02% ± 3.10% HNA+ cells were positive for NESTIN, indicating remnant proliferating progenitors was contained in the grafts (Figure 4D,E). Furthermore, by using cell type specific markers for neurons (pan-ELAVL [Hu]), astrocytes (GFAP), and oligodendrocytes (APC), the transplanted ffiPSC-gNS/PCs differentiated into the three neural lineages: 18.12% ± 1.22% had differentiated into pan-ELAVL (Hu)+ neurons, 27.23% ± 1.92% into GFAP+ astrocytes, and 36.56% ± 2.82% into APC+ oligodendrocytes (Figure 4F).

3.4 | ffiPSC-gNS/PCs-derived mature oligodendrocytes contribute to remyelination

The capacity of ffiPSC-gNS/PCs to differentiate into an oligodendrocyte lineage was of interest because it is usually less abundant to observe oligodendrocyte differentiation in grafted iPS-NS/PCs. Furthermore, remyelination of injured neurons is a desirable therapeutic intervention in SCI. Thus, the contribution of ffiPSC-gNS/PCs...
on remyelination after SCI were further assessed. First, to characterize
the extent of oligodendrocyte differentiation from fflPSC-gNS/PCs, we
performed immunohistochemistry using antibodies against OLIG2
and GST-π (markers for immature and mature oligodendrocytes,
respectively). Within the oligodendrocyte-lineage cells, we found
OLIG2+/GST-π− (immature oligodendrocytes), OLIG2+/GST-π+ (com-
mitted oligodendrocytes), and OLIG2−/GST-π+ cells (mature oligoden-
drocytes) in the grafts (Figure 5A,B). Importantly, 22.73% ± 5.98% of
the fflPSC-gNS/PCs-derived oligodendrocyte-lineage cells were
matured OLIG2−/GST-π+ oligodendrocytes at 12 weeks after

FIGURE 6   Legend on next page.
transplantation. Next, we further examined oligodendrocyte differentiation of ff-iPSC-gNS/PCs by immunohistochemistry using MBP and found that there were several STEM121+/MBP+ areas in the ff-iPSC-gNS/PCs group (Figure 5C,D). Immunoelectron microscopy showed that myelin sheaths were strongly associated with myelin cytoplasm with nanogold-labeled STEM121+ spots (Figure 5E,F). These results indicate that transplanted ff-iPSC-gNS/PCs-derived oligodendrocytes formed mature myelin sheaths on spared axons. To examine the myelinated region in cross-sections of the spinal cord, we visualized myelin sheaths in the injured spinal cord by LFB staining at 12 weeks after transplantation. The LFB+ area was dramatically reduced in the injured spinal cord, indicative of demyelination in the SCI model (Figure 5G).

In contrast, quantitative myelinated areas compared with the PBS group from the epicenter to +0.96 mm rostrocaudal (Figure 5H). Consistently, we found that MBP+ areas in the transplanted group were also significantly larger than those of the PBS group (Figure S4A,B). Taken together, these results indicate that these NS/PCs harbor the capacity to differentiate into mature oligodendrocytes and form myelin sheaths.

Since reconstitution of neuronal circuit is important for functional recovery after SCI and we observed neuronal differentiation of ff-iPSC-gNS/PCs, we also examined the integration of graft-derived neurons into host tissues. To evaluate the capacity of graft-derived neurons to integrate with the host neuronal circuitry, immunostaining was performed using antibodies against HNA, βIII-tubulin, mouse-specific Bassoon (Bsn), and human-specific synaptophysin (hSyn), a presynaptic marker. βIII-tubulin+/HNA+ transplanted cell-derived neurons colocalized with Bsn+ synaptic boutons of host neurons (Figure S5A), while βIII-tubulin+/HNA− host mouse neurons colocalized with hSyn+ synaptic boutons of transplanted cell-derived neurons (Figure S5B). These results indicate that the transplanted cell-derived neurons integrated with host neuronal circuits and formed synapses. Furthermore, since reticulospinal tract (RtST) is known as a spinal cord tract that plays an important role in the initiation of locomotion and postural control,60,61 we evaluated RtST fiber regeneration from the brain stem. The BDA-mediated consecutive neuronal fiber tracing was performed 91 days after transplantation (Figure 5C). The ff-iPSC-gNS/PCs group tended to have larger BDA-labeled RtST areas compared with the PBS group, but there was almost no significant difference between the two groups (Figure S3D), indicating that the regeneration of neuronal circuits of RtST was less likely to be triggered by transplantation of gNS/PCs.

### 3.5 | Transplanted ff-hiPSC-gNS/PCs enhance functional recovery following SCI

Finally, recovery of locomotor function was evaluated by the BMS score,62 rotarod test,59,63 treadmill gait analysis using the DigiGait system and kinematic analysis. The BMS score showed significantly improved motor function in the ff-iPSC-gNS/PCs group compared with that in the control PBS group at 14 days after SCI, and functional recovery was significant thereafter (Figure 6A). Body weight was also significantly increased in the ff-iPSC-gNS/PCs group (Figure S3C), consistent with a previous report.63 The gait performance of the mice in the two groups was examined using the rotarod test and the DigiGait system at 12 weeks after transplantation. In the ff-iPSC-gNS/PCs group, treadmill gait analysis showed a significantly longer stride length and smaller paw angle (Figure 6B,C). The mice transplanted with the NS/PCs ran on the rotating rod for a significantly longer time than those given PBS (Figure 6D). To evaluate the gait and movement of each joint in more detail, kinematic analysis was performed at 12 weeks after transplantation. Representative stick diagrams of hind limb movements of the swing phase indicate that the ff-iPSC-gNS/PCs group had a smoother step and a more consistent step cycle than the control group (Figure 6E,F). Furthermore, each joint moved with less variation in the ff-iPSC-gNS/PCs group (Figure 6G,H), and various types of joint function in the ff-iPSC-gNS/PCs group were significantly improved compared with those in the control group (Figure S6).

To evaluate the spinal stretch reflex, which plays an important role in locomotion, electrophysiological examination was performed using the H-reflex at 12 weeks after transplantation. The amplitude of the H-reflex was significantly lower in the ff-iPSC-gNS/PCs group compared with that in the PBS group (Figure 6I). Together, these results indicate that the gait in the ff-iPSC-gNS/PCs group was also improved compared with that in the control group, suggesting that ff-iPSC-gNS/PCs restore function of residual neuronal fibers to enable precise gait coordination.

**FIGURE 6** Motor function analyses after transplantation of feeder-free hiPSCs (ff-iPSCs)-gNS/PCs. A. Comparison of Basso Mouse Scale (BMS) scores between the PBS and ff-iPSC-gNS/PCs groups. The BMS scores showed significantly functional recovery in the ff-iPSC-gNS/PCs group compared with that in the PBS group at 14 days after SCI and thereafter. Values are means ± SEM (control group, n = 12; ff-iPSC-gNS/PCs group, n = 14; *P < .05). B,C. Comparison of stride lengths (B) and paw angles (C) between the PBS and ff-iPSC-gNS/PCs groups. Treadmill gait analysis was performed at 12 weeks after transplantation using the DigiGait system. Stride length and stance angle were significantly longer and more parallel, respectively, in the ff-iPSC-gNS/PCs group than in the PBS group. Values are means ± SEM (control group, n = 12; ff-iPSC-gNS/PCs group, n = 14; *P < .05 *P < .01). D. Comparison of rotarod test results between the PBS and ff-iPSC-gNS/PCs groups. The rotarod test was performed at 12 weeks after transplantation. The ff-iPSC-gNS/PCs group ran on the rod for significantly longer than the PBS group. Values are means ± SEM (control group, n = 12; ff-iPSC-gNS/PCs group, n = 14; *P < .05). E,F. Representative kinematics stick diagrams at 12 weeks after transplantation. G,H. Mean (SD) waveforms of hip (Hip), knee (Knee), ankle (Ankle), and toe (Toe) joint angle during treadmill locomotion. I. Comparison of H-reflex between the PBS and ff-iPSC-gNS/PCs groups using electrophysiological analyses at 12 weeks after transplantation. The amplitude was significantly smaller in the ff-iPSC-gNS/PCs group than in the PBS group. Values are means ± SEM. gNS/PCs, neural stem/progenitor cells with gliogenic competence; PBS, phosphate-buffered saline.
4 | DISCUSSION

Cell replacement has been proposed to treat neurotraumatic injuries, including SCI. In this study, we established robust methods to generate gNS/PCs for treatment of SCI using clinically relevant iPSCs which had been prepared from an HLA-homozygous super donor. One of the main complications in cell replacement therapy is immune rejection of transplanted allograft cells. Although autologous transplantation is ideal to prevent rejection, clinical grade iPSCs are costly and time consuming to generate and prepare for each patient. Allogenic transplantation using HLA-matched iPSCs is a more realistic and preferred option for clinical application because immune rejection would be minimal using HLA-matched donors and patients, as suggested by a non-human primate study showing that major histocompatibility complex (MHC)-matching could improve the engraftment of iPSC-derived neurons.64 In Japan, HLA-A*24:02, HLA-B*52:01, and HLA-DRB*15:02 haplotypes are the most frequent (8.5%), and the HLA-homozygous iPSCs used in the current study matched ~20% of the Japanese population.65 Thus, the current procedure to generate gNS/PCs together with iPSCs from a few homozygous donors (super donors) with broad HLA immune-compatibility would allow for a significant percentage of the population to benefit from iPSC-based cell therapy.27

In addition to the protocols we presented in this study, there are several other procedures available to obtain gliogenic NS/PCs19,21,22,66,67 (Table S1). Although we did not directly compare these protocols, our protocol has certain advantages in terms of the required culture period to obtain MBP+ oligodendrocytes and higher yield to obtain glial cells. After transplantation, gNS/PCs differentiated into three neural lineages, including neurons, astrocytes, and oligodendrocytes (Figure 4E). As for oligodendrocyte differentiation, we observed contribution of gNS/PCs to remyelination in injured spinal cord (Figure 5D-F). It is worth noting that gNS/PCs-derived OLIG2+ GST-α− immature oligodendrocytes were still present among the grafts (Figure 5A,B). Given that OLIG2 is indicative of migrating oligodendrocytes68 and that 77% of cells in the oligodendrocyte lineages still expressed OLIG2 (Figure 5B) at 12 weeks after transplantation, the gNS/PCs-derived cells that had entered oligodendrocyte lineages still theoretically harbor the potential to promote functional recovery by further remyelination. Oligodendrocyte precursors migrate toward demyelinated lesions69; therefore, the residual OLIG2+ cells would remyelinate the demyelinated axons over time. Further functional recovery would be enhanced in SCI animal models by rehabilitation, possibly through ongoing myelination together with continued axonal regeneration and synaptogenesis as previously described.70 There is a series of reports demonstrating restoration and/or reorganization of neuronal circuits by graft-derived neurons in SCI animals after NS/PC-transplantation.71 Although we did not observe significant regeneration of the RtST, gNS/PCs still hold the capacity of neuronal differentiation and functional motor recovery might be acquired by neurons differentiated from gNS/PCs (Figure 4D). Indeed, we observed synapse formation between host and gNS/PCs-derived neurons (Figure SSA,B), providing mechanistic insight into the functional recovery observed after transplantation. Taken together, remyelination of damaged tissues in addition to neuronal replacement would be mediated by gNS/PCs to enhance functional recovery of SCI after transplantation.

One might ask whether gNS/PCs exerted functional recovery more efficiently than neurogenic NS/PCs. In our previous reports using integration-free iPSCs,34 functional recovery after transplantation was not obvious using neurogenic NS/PCs, indicating that gNS/PCs are more beneficial for SCI patients in clinical settings. Indeed, we transplanted nNS/PCs derived from same parental iPSCs and did not observe functional recovery after the transplantation, indicating that gNS/PCs are superior cell sources for cell-based therapy for SCI (Figure S7). Importantly, this observation might be supported by the previous finding using directly reprogrammed NS/PC from somatic cells.9 They also found more beneficial aspects of NS/PCs which had capacity to differentiate into oligodendrocytes. To acquire cell source for transplantation via directly reprogramming approach might be more realistic in the setting of autologous transplantation. Although, it would be challenging to prepare large amounts of cells with quality assurance for autologous without bypassing iPSCs, cell-therapy relying on NS/PCs with gliogenic differentiation capacity hold promising therapeutic potential. However, gNS/PCs-derived oligodendrocytes still need residual host neurons, which are demyelinated upon SCI. Therefore, criteria to identify SCI patients who will display functional recovery with gNS/PCs should be determined and examined in future studies.

The current study has several limitations that should be discussed. First, although iPSCs provided by CiRA were generated and maintained under good manufacture practice (GMP)-conditions,27 the current condition to generate gNS/PCs are not xeno-free, which does not fulfill the criteria for GMP-quality. To meet the GMP-grade culture condition, several supplements utilized in our procedures including B27 should be replaced with GMP-grade xeno-free products. Second, we used iPSC lines that are homozygous for the most frequent HLA haplotype. A previous study estimated that iPSCs with 50 unique homozygous HLA haplotypes would match ~90% of the Japanese population.72 Thus, future studies need to validate whether the current approach to generate gNS/PCs is applicable across different HLA-homozygous iPSCs. Third, although we observed functional recovery, the most important cell types for functional recovery of SCI after transplantation are still unclear. Future studies should seek to develop a procedure to bias NS/PCs toward selected cell lineages that exhibit greater therapeutic potential against neurotraumatic injuries.

5 | CONCLUSION

We established a robust protocol to generate gNS/PCs from clinically relevant iPSCs. The gNS/PCs derived from HLA-homozygous iPSCs exhibited prominent favorable outcomes after transplantation into an SCI animal model, providing a promising cell source for treating SCI in future clinical settings.
ACKNOWLEDGMENTS
We thank CIRA for providing iPSCs. We also thank Dr Yonehiro Kanemura for providing neurogenic iPSC-nNS/PCs. We appreciate Ms T. Harada, Ms K. Yasutake, Ms M. Akizawa, and all members of the Spinal Cord Research Team in the Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan. We also appreciate Dr Tetsutaroh Hayashi and Dr Itoshi Nikaido for providing the technology of RamDA-seq. This work was supported by the Research Center Network for Realization of Regenerative Medicine of the Japan Science and Technology Agency (JST), the Japan Agency for Medical Research and Development (AMED) (Grant 18bm040022h0201 to M. Isoda, Grant 15bm0204001h003 to H.O. and M.N., Grant 18bm040022h0001 to J.K.), and by a medical research grant related to traffic accidents from the General Insurance Association of Japan to Y.K. We thank Jeremy Allen, PhD from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

CONFLICT OF INTEREST
H.O. is a compensated scientific consultant of San Bio, Co., Ltd., and K Pharma, Inc. and has received research funding from Dainippon Sumitomo Pharmaceutical Co.Ltd. M.N. is a compensated scientific consultant of K Pharma, Inc. M. Isoda and M. Inoue are employed by Sumitomo Dainippon Pharma. The other authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
Y.K., M. Isoda: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; T. Sanosaka: collection and assembly of data, data analysis and interpretation; R.S., S.I., T.O., M.S., M. Inoue: reviewing and editing the manuscript; H.N.: reviewing and editing the manuscript, final approval of manuscript; J.K.: conception and design, financial support, administrative support, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT
All RNA-seq data have been deposited with the Gene Expression Omnibus (GEO) database under accession number GSE138426. The data sets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

ORCID
Hideyuki Okano https://orcid.org/0000-0002-6505-7310
Jun Kohyama https://orcid.org/0000-0001-8168-8588

REFERENCES
1. Mothe AJ, Tator CH. Review of transplantation of neural stem/progenitor cells for spinal cord injury. Int J Dev Neurosci. 2013;31(7):701-713.
2. Lee BB, Cripps RA, Fitzharris M, Wing PC. The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate. Spinal Cord. 2014;52(2):110-116.
3. Shingu H, Ohama M, Ikata T, et al. A nationwide epidemiological survey of spinal cord injuries in Japan from January 1990 to December 1992. Paraplegia. 1995;33(4):183-188.
4. Ogawa Y, Sawamoto K, Miyata T, et al. Transplantation of in vitro expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res. 2002;69(6):925-933.
5. Iwanami A, Kaneko S, Nakamura M, et al. Transplantation of human neural stem cells for spinal cord injury in primates. J Neurosci Res. 2005;80(2):182-190.
6. Cummings BJ, Uchida N, Tamaki SJ, et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci USA. 2005;102(39):14069-14074.
7. Suzuki H, Ahuja CS, Salewski RP, et al. Neural stem cell mediated recovery is enhanced by chondroitinase ABC pretreatment in chronic cervical spinal cord injury. Proc Natl Acad Sci USA. 2017;12(8):e0182339.
8. Manley NC, Priest CA, Denham J, Wirth ED III, Lebkowski JS. Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. STEM CELLS TRANSLATIONAL MEDICINE. 2017;6(10):1917-1929.
9. Nagoshi N, Khazaei M, Ahlfors JE, et al. Human spinal oligodendrogenic neural progenitor cells promote functional recovery after spinal cord injury by axonal remyelination and tissue sparing. STEM CELLS TRANSLATIONAL MEDICINE. 2018;7(11):806-818.
10. Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018;82(4):562-575.
11. Ramotowski C, Qu X, Villa-Díaz LG. Progress in the use of induced pluripotent stem cell-derived neural cells for traumatic spinal cord injuries in animal populations: meta-analysis and review. STEM CELLS TRANSLATIONAL MEDICINE. 2019;8:681-693.
12. Nori S, Okada Y, Yasuda A, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci USA. 2011;108(40):16825-16830.
13. Kobayashi Y, Okada Y, Itakura G, et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 2012;7(12):e52787.
14. Okubo T, Iwanami A, Kohyama J, et al. Pretreatment with a gamma-secretase inhibitor prevents tumor-like overgrowth in human iPSC-derived transplants for spinal cord injury. Stem Cell Reports. 2016;7(4):649-663.
15. Okubo T, Nagoshi N, Kohyama J, et al. Treatment with a gamma-secretase inhibitor promotes functional recovery in human iPSC-derived transplants for chronic spinal cord injury. Stem Cell Reports. 2018;11(6):1416-1432.
16. Kumagai G, Okada Y, Yamane J, et al. Roles of ES cell-derived glionic spinal neural stem/progenitor cells in functional recovery after spinal cord injury. PLoS One. 2009;4(11):e7706.
17. Yasuda A, Tsuji O, Shibata S, et al. Significance of remyelination by neural stem/progenitor cells transplanted into the injured spinal cord. STEM CELLS. 2011;29(12):1983-1994.
18. Romanyuk N, Amemori T, Turnovcova K, et al. Beneficial effect of human induced pluripotent stem cell-derived neural precursors in spinal cord injury repair. Cell Transplant. 2015;24(9):1781-1797.
19. Douvaras P, Fossati V. Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat Protoc. 2015;10(8):1143-1154.
20. Gorris R, Fischer J, Erwes KL, et al. Pluripotent stem cell-derived radial glia-like cells as stable intermediate for efficient generation of human oligodendrocytes. Glia. 2015;63(12):2152-2167.
21. Marton RM, Miura Y, Sloan SA, et al. Differentiation and maturation of oligodendrocytes in human three-dimensional neural cultures. Nat Neurosci. 2019;22(3):484-491.
22. Wang S, Bates J, Li X, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell. 2013;12(2):252-264.

23. Numasawa-Kuroiwa Y, Okada Y, Shibata S, et al. Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Reports. 2014;2(5):648-661.

24. Najm FJ, Zaremba A, Caprariello AV, et al. Rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells. Nat Methods. 2011;8(11):957-962.

25. Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: the Kyoto trial. Prog Brain Res. 2017;230:213-226.

26. Umekage M, Sato Y, Takasu N. Overview: an iPSC cell stock at CIRA. Inflamm Regen. 2019;39:17.

27. Nakagawa M, Taniguchi Y, Senda S, et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014;4:3594.

28. Okita K, Yamakawa T, Matsumura Y, et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31(3):458-466.

29. Fukusumi H, Shofuda T, Bamba Y, et al. Establishment of human neural progenitor cells from human induced pluripotent stem cells with diverse tissue origins. Stem Cells Int. 2016;2016:7235757.

30. Scheff SW, Rabchevsky AV, Fugaccia I, et al. Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma. 2003;20(2):179-193.

31. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, Mctigue DM, Popovich PG. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006;23(5):635-659.

32. Okano H, Yamanaka S. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain. 2014;7:22.

33. Kim DS, Lee JS, Leem JW, et al. Robust enhancement of neural differentiation from human ES and iPES cells regardless of their innate difference in differentiation propensity. Stem Cell Rev Rep. 2010;6(2):270-281.

34. Sugai K, Fukuzawa R, Shofuda T, et al. Pathological classification of human iPSC-derived neural stem/progenitor cells towards safety assessment of transplantation therapy for CNS diseases. Mol Brain. 2016;9(1):85.

35. Bennett CN, Ross SE, Longo KA, et al. Regulation of Wnt signaling during adiogenesis. J Biol Chem. 2002;277(34):30998-31004.

36. Kim WY, Wang X, Wu Y, et al. GSK-3 is a master regulator of neuronal progenitor homeostasis. Nat Neurosci. 2009;12(11):1390-1397.

37. Yao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 2009;136(6):1017-1031.

38. Li W, Sun W, Zhang Y, et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci USA. 2011;108(20):8299-8304.

39. Okada Y, Shimazaki T, Sobue G, Okano H. Retinoic-acid-concentration-dependent acquisition of neural cell identity during in vitro differentiation of mouse embryonic stem cells. Dev Biol. 2004;275(1):124-142.

40. Soula C, Danesin C, Kan P, Grob M, Poncet C, Cochart P. Distinct sites of origin of oligodendrocytes and somatic motoneurons in the chick spinal cord: oligodendrocytes arise from Nkx2.2-expressing progenitors by a Shh-dependent mechanism. Development. 2001;128(8):1369-1379.

41. Zhou Q, Choi G, Anderson DJ. The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron. 2001;31(5):791-807.

42. Richardson WD, Kessaris N, Pringle N. Oligodendrocyte waves. Nat Rev Neurosci. 2006;7(1):11-18.
62. Okada S, Nakamura M, Mikami Y, et al. Blockade of interleukin-6 receptor suppresses reactive astroglisis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res. 2004;76(2):265-276.

63. Ormond DR, Shannon C, Oppenheim J, et al. Stem cell therapy and curcumin synergistically enhance recovery from spinal cord injury. PLoS One. 2014;9(2):e88916.

64. Morizane A, Kikuchi T, Hayashi T, et al. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017;8(1):385.

65. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409-412.

66. Madhavan M, Nevin ZS, Shick HE, et al. Induction of myelinating oligodendrocytes in human cortical spheroids. Nat Methods. 2018;15(9):700-706.

67. Nevin ZS, Factor DC, Karl RT, et al. Modeling the mutational and phenotypic landscapes of Pelizaeus-Merzbacher disease with human iPSC-derived oligodendrocytes. Am J Hum Genet. 2017;100(4):617-634.

68. Wegener A, Deboux C, Bachelin C, et al. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination. Brain. 2015;138(pt 1):120-135.

69. Piaton G, Aigrot MS, Williams A, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain. 2011;134(pt 4):1156-1167.

70. Tashiro S, Nishimura S, Iwai H, et al. Functional recovery from neural stem/progenitor cell transplantation combined with treadmill training in mice with chronic spinal cord injury. Sci Rep. 2016;6:30898.

71. Abematsu M, Tsujimura K, Yamano M, et al. Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J Clin Invest. 2010;120(9):3255-3266.

72. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26(7):739-740.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Kamata Y, Isoda M, Sanosaka T, et al. A robust culture system to generate neural progenitors with gliogenic competence from clinically relevant induced pluripotent stem cells for treatment of spinal cord injury. STEM CELLS Transl Med. 2021;10:398-413. [https://doi.org/10.1002/sctm.20-0269](https://doi.org/10.1002/sctm.20-0269)